Several other genetic lesions have been identified in prostate cancer, such as SRD5A (steroid-5-alpha-reductase alpha polypeptide) [4], androgen receptor [5], estrogen receptor-β [6], E-cadherin [7], and toll-like receptors [8–10]. Here, CDH1 is linked to prostate cancer.